176 related articles for article (PubMed ID: 24370904)
21. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness.
Lai HC; Chung WM; Chang CM; Liao PY; Su YT; Yeh CC; Jeng LB; Ma WL; Chang WC
Anticancer Res; 2020 Mar; 40(3):1285-1295. PubMed ID: 32132025
[TBL] [Abstract][Full Text] [Related]
23. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
24. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
Li Y; Farmer RW; Yang Y; Martin RC
BMC Cancer; 2016 Mar; 16():228. PubMed ID: 26984381
[TBL] [Abstract][Full Text] [Related]
25. High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.
Henrich CJ; Budhu A; Yu Z; Evans JR; Goncharova EI; Ransom TT; Wang XW; McMahon JB
Chem Biol Drug Des; 2013 Aug; 82(2):131-9. PubMed ID: 23879724
[TBL] [Abstract][Full Text] [Related]
26. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
27. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
Yamashita T; Budhu A; Forgues M; Wang XW
Cancer Res; 2007 Nov; 67(22):10831-9. PubMed ID: 18006828
[TBL] [Abstract][Full Text] [Related]
28. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
29. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.
Yamashita T; Forgues M; Wang W; Kim JW; Ye Q; Jia H; Budhu A; Zanetti KA; Chen Y; Qin LX; Tang ZY; Wang XW
Cancer Res; 2008 Mar; 68(5):1451-61. PubMed ID: 18316609
[TBL] [Abstract][Full Text] [Related]
30. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
31. Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells.
Nagahara T; Shiraha H; Sawahara H; Uchida D; Takeuchi Y; Iwamuro M; Kataoka J; Horiguchi S; Kuwaki T; Onishi H; Nakamura S; Takaki A; Nouso K; Yamamoto K
Oncol Rep; 2015 Sep; 34(3):1169-77. PubMed ID: 26165819
[TBL] [Abstract][Full Text] [Related]
32. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
33. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
34. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
36. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
[TBL] [Abstract][Full Text] [Related]
37. Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Liu Y; Bi T; Dai W; Wang G; Qian L; Gao Q; Shen G
Tumour Biol; 2016 Jun; 37(6):7589-97. PubMed ID: 26687645
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Murakami M; Kobayashi S; Marubashi S; Tomimaru Y; Noda T; Wada H; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Ann Surg Oncol; 2011 Feb; 18(2):589-96. PubMed ID: 20811948
[TBL] [Abstract][Full Text] [Related]
39. Expression of epithelial cell adhesion molecule associated with elevated ductular reactions in hepatocellar carcinoma.
Xu M; Qian G; Xie F; Shi C; Yan L; Yu L; Zheng T; Wei L; Yang J
Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):699-705. PubMed ID: 24924904
[TBL] [Abstract][Full Text] [Related]
40. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
